Medication info
Valsartan and Rosuvastatin Tablet 10/160 mg

Valsartan and Rosuvastatin Tablet 10/160 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP) * 3]
Approval status
Active

MFDS item code 202003854 · Approved 2020.05.26 · Insurance code 649807680

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; reduction of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When co-administered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, after which the dose should be increased over several weeks, according to patient tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed when creatinine clearance is 10 mL/min or higher. However, as there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is needed. 3. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, this medicine (a combination product containing the same amounts of each active ingredient) may be substituted for convenience.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; reduction of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • heart failure
  • heart failure intolerant to ACE inhibitors
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
View approved original text

This medication is used for patients who need to receive both valsartan and rosuvastatin simultaneously. First, valsartan is used for essential hypertension, heart failure, particularly in heart failure patients intolerant to ACE inhibitors, and reduces the risk of death in patients with left ventricular dysfunction after myocardial infarction. Meanwhile, rosuvastatin is used to treat hypercholesterolemia and dyslipidemia patients, serving as an adjunct when dietary and exercise controls are insufficient. Additionally, it reduces the risk of cardiovascular diseases, thereby decreasing the chance of stroke, myocardial infarction, and arterial revascularization procedures. Therefore, this medication effectively improves cardiovascular health by managing blood pressure and lipids simultaneously.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When co-administered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, after which the dose should be increased over several weeks, according to patient tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is needed when creatinine clearance is 10 mL/min or higher. However, as there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is needed. 3. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, this medicine (a combination product containing the same amounts of each active ingredient) may be substituted for convenience.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication should not be used during pregnancy. It may cause serious harm to the fetus and newborn, so use should be immediately discontinued upon confirmation of pregnancy. Patients with an allergy to this medication, severe liver or kidney dysfunction, or muscle diseases should not take this medication. Elderly patients or those with weakened liver function or high blood potassium levels should exercise special caution when using this medication. This medication may cause muscle pain or weakness, and rarely severe muscle damage, so if any unusual muscle symptoms occur, consultation with a doctor is advised. Liver function abnormalities or changes in blood test results may occur, so regular monitoring during treatment is recommended. There can be cases where blood pressure drops suddenly, so if you experience dizziness or feel faint, immediate reporting is necessary. Interactions may occur when taking with other medications, so it's important to inform your doctor or pharmacist of all medications you are taking. It is advisable for breastfeeding women not to use this medication; if unavoidable, breastfeeding should be discontinued. Safety and efficacy have not been established for children and adolescents under 18 years of age, so it should not be used in this population. In the case of an overdose, there is no specific antidote, so you must go to the hospital immediately for appropriate treatment. This medication should be kept out of reach of children, and it's best not to transfer it to other containers. If any abnormal symptoms occur while taking this medication, it is crucial to consult with healthcare providers for appropriate action.

Side effects

  • Dyspepsia
  • nausea
  • chest discomfort
  • dizziness
  • headache
  • conjunctival hemorrhage
  • constipation
  • asthenia
  • chest pain
  • facial swelling
Show 132 more
  • peripheral edema
  • nasopharyngitis
  • urinary tract infection
  • contusion
  • increased serum transaminases (AST, ALT)
  • increased serum creatine phosphokinase
  • increased serum potassium
  • increased gamma-glutamyl transferase
  • musculoskeletal rigidity
  • limb pain
  • sensory loss
  • anxiety
  • upper respiratory infection
  • pharyngitis
  • tonsillitis
  • spinal stenosis
  • aphasia
  • oral hemorrhage
  • vomiting
  • insulin-dependent diabetes mellitus
  • diabetic complications
  • leg fracture
  • spinal fracture
  • fracture
  • skin neoplasm
  • second-degree atrioventricular block
  • vestibular neuritis
  • retinal detachment
  • unspecified skin tumor-like condition
  • herpes zoster
  • intervertebral disc herniation
  • hemoptysis
  • sputum disease
  • bronchitis
  • dysesthesia
  • hoarseness
  • gastroesophageal reflux
  • diverticulitis
  • gastritis
  • stomatitis
  • carpal tunnel syndrome
  • chills
  • facial flushing
  • increased blood sugar
  • increased triglycerides
  • elevated blood pressure
  • exacerbation of hypertension
  • neck/shoulder pain
  • toe fracture
  • osteomyelitis
  • skin infection
  • unspecified skin inflammation
  • localized skin reaction
  • palpitations
  • exacerbation of angina
  • auditory disturbances
  • overactive bladder
  • increased serum creatinine
  • benign prostatic hyperplasia
  • laceration
  • headache
  • dizziness
  • viral infection
  • upper respiratory infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
  • abdominal cramps
  • pharyngitis
  • arthralgia
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal impairment
  • hyperkalemia
  • drowsiness
  • atrial fibrillation
  • polydipsia
  • anorexia
  • malaise
  • vascular edema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • hepatitis
  • arrhythmia
  • intestinal vascular edema
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • syncope
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • decreased hematocrit
  • decreased hemoglobin
  • neutropenia
  • increased serum creatinine
  • increased total bilirubin
  • increased BUN
  • polyneuropathy
  • memory loss
  • peripheral neuropathy
  • dyspnea
  • thrombocytopenia
  • jaundice
  • Stevens-Johnson syndrome
  • urticaria
  • myalgia
  • myopathy
  • immune-mediated necrotizing myopathy
  • lupus-like syndrome
  • muscle rupture
  • arthralgia
  • immune-mediated necrotizing myopathy
  • hematuria
  • edema
  • depression
  • sleep disorders
  • interstitial lung disease
  • sexual dysfunction
  • gynecomastia
  • hepatic failure
  • cognitive impairment
  • severe myasthenia gravis
  • ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to light, so it should be stored in a special container that does not allow light in. Additionally, when storing the medication, it is important to maintain a temperature between 1 degree and 30 degrees Celsius. This helps to preserve the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP) * 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.